# Poolbeg Pharma POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-polb-001-data-to-be-presented-at-american-society-of-hematology-annual-meeting/4121131936
- Published: 2023-11-03T07:09:28+00:00
- Author: Ethan Davis

**[Poolbeg Pharma Plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)**(
[LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with
a high unmet medical need, has announced that an abstract detailing POLB 001’s promise
as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies
has been accepted for presentation at 65th American Society of Hematology (‘ASH’)
Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego, California.

The ASH Annual Meeting and Exposition is recognised as the world’s premier conference
focussing on haematological malignancies (blood cancers) and brings together over
25,000 industry and academic attendees each year to share the latest scientific 
discoveries and advances in clinical care.

Poolbeg Pharma’s poster presentation will provide insight into the results obtained
from the POLB 001 LPS human challenge trial, highlighting its potential use in the
treatment of Cytokine Release Syndrome (CRS) associated with severe influenza and
cancer immunotherapies. Mild to moderate cases of CRS require hospitalisation and
can impact the ability to deliver the cancer immunotherapies, severe cases of CRS
can become life-threatening and may require intensive care, and in rare cases cause
mortality. An effective therapy for CRS associated with cancer immunotherapies has
the potential to make these treatments more tolerable for individual patients to
enable them to best benefit from their treatment and to make cancer immunotherapies
more widely accessible.

**Title:** POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential
to Prevent Cytokine Release Syndrome (CRS)

**Session Name:** 704. Cellular Immunotherapies: Early Phase and Investigational
Therapies: Poster I

**Session Date:** Saturday, December 9, 2023

**Presentation Time:** 5:30 PM – 7:30 PM

**Presenter:** Dr Emma Searle, Consultant Hematologist and Honorary Senior Lecturer
at University of Manchester

**Location:** San Diego Convention Center, Halls G-H

> **Dr Emma Searle, Consultant Hematologist and Honorary Senior Lecturer at University
> of Manchester, said:** “_Having_ _this abstract accepted at ASH represents a strong
> validation of POLB 001’s potential in addressing CRS in oncology._ _Cytokine Release
> Syndrome is highly prevalent among patients receiving immunotherapy for haematological
> malignancies. The positive data from the LPS challenge trial has highlighted that
> oral treatment of POLB 001 holds great promise in tackling this issue; potentially
> leading to improved patient outcomes, reduced strain on healthcare systems while
> making these treatments more accessible to a broader patient population.”_

If you would like to meet with Poolbeg Pharma to discuss POLB 001, get in touch:
[partnering@poolbegpharma.com](https://www.directorstalkinterviews.com/poolbeg-pharma-polb-001-data-to-be-presented-at-american-society-of-hematology-annual-meeting/partnering@poolbegpharma.com)

Share on:
